Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Novel agents have improved multiple myeloma (MM) outcomes.
• Treatment decisions are complicated by response heterogeneity, numerous options, and cost.
• Response-adapted therapy is underutilized in MM despite success in other hematologic cancers.

Purpose of the Study:

• To review current response-adapted therapeutic strategies in MM.
• To discuss the future implementation and improvement of these strategies in treatment algorithms.

Main Methods:

• Review of existing literature on response-adapted therapy in MM.
• Analysis of the role of minimal residual disease (MRD) in treatment adaptation.
• Consideration of novel response assessment techniques, including sensitive paraprotein quantification and imaging.

Main Results:

• Early response criteria alone may not predict long-term outcomes.
• Minimal residual disease (MRD) is a significant prognostic factor, enabling MRD-adapted strategies.
• Advanced techniques offer sensitive and holistic response assessments for clinical trials.

Conclusions:

• Response-adapted algorithms can personalize MM treatment, maximizing efficacy and minimizing toxicity/cost.
• Standardizing MRD methodology is crucial for future trials.
• Incorporating imaging and defining optimal management for MRD-positive patients are key research questions.